Australian anti-COVID nasal spray gets state funding for human testing

Organisation: Position: Deadline Date: Location:

A new nasal spray with the potential to fight COVID-19 and other respiratory viral infections will be tested in the hopes of manufacturing it in Australia, reports New Daily.

The INNA-051 nasal treatment, developed by Australian biotech company Ena Respiratory, targets the primary site of most respiratory infections, including COVID-19. Applied topically with a spray, the treatment activates the immune defence mechanisms in the respiratory tract.

The technology could also help fight coronavirus and other infections like influenza and the common cold.

The federal government announced that along with a private partner it would provide $11.7 million to fund the testing, as part of the Biomedical Translation Fund. If tests are successful, the product will be manufactured in Australia.

 

Full New Daily report

 

See also:

 

MedicalBrief Archives: Preventive nasal spray cuts viral replication in half in Australian animal study

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.